🟢 Anixa Biosciences is trading 5.7% up today after Australian patent acceptance for breast cancer vaccine

Anixa Biosciences is trading at $3.70 (+5.71%) in pre-market following news of a patent acceptance in Australia for its breast cancer vaccine technology.

• The Australian patent acceptance on July 14 has sustained positive sentiment, building on a 10.7% gain during the previous trading session.
• The upward move appears company-specific as broader markets show weakness in pre-market trading.
• Continued interest in the company's oncology pipeline and biotech developments is driving the current momentum.